BAYER AG NA O.N./ DE000BAY0017 /
12/11/2024 21:56:23 | Diferencia -3.270 | Volumen | Bid21:56:23 | Ask21:56:23 | Capitalización de mecado | Dividendo A. | P/E Ratio |
---|---|---|---|---|---|---|---|
21.015EUR | -13.47% | - Volumen de negocios: - |
21.015Volumen de oferta: - | 21.120Tamaño/ Volumen/ Formato de Ask: - | 20.72 mil millonesEUR | 0.52% | - |
GlobeNewswire
02/08
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...
GlobeNewswire
11/07
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...
GlobeNewswire
30/05
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire
30/05
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
28/05
Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement
GlobeNewswire
02/05
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire
18/04
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire
16/04
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire
11/04
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire
25/03
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire
06/03
BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página